Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Christopher MelaniRahul LakhotiaStefania PittalugaJames D PhelanDa Wei HuangGeorge WrightJillian SimardJagan MuppidiCraig J ThomasMichele CeribelliFrances A TostoYandan YangWeihong XuTheresa Davies-HillSvetlana D PackCody J PeerOluwatobi ArisaEsther MenaLiza LindenbergEthan BergvallCraig A PortellRafic J FarahSeung Tae LeeAmynah PradhanCandis MorrisonAtekelt TadeseAnna Marie JuanitezCrystal LuAllison JacobHeidi SimmonsWilliam Douglas FiggSeth M SteinbergElaine S JaffeMark J RoschewskiLouis M StaudtWyndham H WilsonPublished in: The New England journal of medicine (2024)
Treatment with ViPOR was associated with durable remissions in patients with specific molecular DLBCL subtypes and was associated with mainly reversible adverse events. (Funded by the Intramural Research Program of the National Cancer Institute and the National Center for Advancing Translational Sciences of the National Institutes of Health and others; ClinicalTrials.gov number, NCT03223610.).